Tiragolumab Combo Does Not Reach Survival End Points in Nonsquamous NSCLC Developers intend to halt the phase 2/3 SKYSCRAPER-06 trial assessing tiragolumab plus atezolizumab and chemotherapy in nonsquamous NSCLC. GTB-3650 Snags FDA Clearance for IND Application in CD33+ Leukemia Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.
Videos Experts on multiple myeloma provide clinical insights on supportive care strategies for patients experiencing infections or secondary malignancies following CAR T-cell therapy.
Watch Now Key opinion leaders examine the application of tyrosine kinase inhibitors (TKIs) and evaluate first-line therapeutic approaches for renal cell carcinoma.
Watch Now Trending Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
  Acalabrutinib Appears More Effective in Earlier Lines of Treatment for CLL A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
 

  Featured Video  

  Featured Video